The phase III IMbrave150 study evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) demonstrated statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared with sorafenib in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
